Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription

Table 2 Effect of adriamycin combined with metformin on the proliferation of HepG2/adriamycin cells (n = 3, mean ± SD)

Adriamycin (μmol/L)	24 h		48 h		72 h
	Control	Metformin	Control	Metformin	Control	Metformin
0	1.434 ± 0.03	1.327 ± 0.04a	1.477 ± 0.08	1.357 ± 0.01	1.695 ± 0.08	1.507 ± 0.05a
0.01	1.280 ± 0.06	1.160 ± 0.01a	1.489 ± 0.03	1.314 ± 0.03a	1.505 ± 0.01	1.378 ± 0.07a
0.1	1.194 ± 0.10	1.111 ± 0.09	1.418 ± 0.01	1.213 ± 0.02a	1.453 ± 0.02	1.249 ± 0.04a
1	0.847 ± 0.02	0.662 ± 0.02a	0.661 ± 0.01	0.661 ± 0.06	0.753 ± 0.04	0.508 ± 0.04a
5	0.628 ± 0.08	0.458 ± 0.02a	0.358 ± 0.02	0.208 ± 0.03a	0.347 ± 0.03	0.194 ± 0.03a
10	0.531 ± 0.00	0.399 ± 0.01a	0.162 ± 0.01	0.062 ± 0.01a	0.122 ± 0.01	0.049 ± 0.01a
20	0.284 ± 0.01	0.162 ± 0.01a	0.143 ± 0.01	0.051 ± 0.00a	0.084 ± 0.01	0.027 ± 0.00a

^aP < 0.05 vs the control group. The proliferation of HepG2/adriamycin cells calculated with SPSS21.0 is presented as mean ± SD from CCK-8 assay in triplicate.